Efruxifermin: A Potential Breakthrough Treatment for Compensated Cirrhosis Due to MASH

Published / Modified Jun 11 2024
CSIMarket Team / CSIMarket.com

In recent years, the burden of metabolic dysfunction-associated steatohepatitis (MASH) has risen significantly, necessitating the development of innovative therapeutics. Akero Therapeutics, a clinical-stage biopharmaceutical company, has been at the forefront of this endeavor, making notable advancements in the treatment of patients with serious metabolic diseases. This article will discuss the exciting Phase 3 SYNCHRONY Outcomes trial initiated by Akero Therapeutics to evaluate the efficacy and safety of their groundbreaking drug, efruxifermin (EFX), in patients with compensated cirrhosis (F4) due to MASH. It will also delve into the previously reported statistically significant histological improvements observed in the Phase 2b HARMONY study, further supporting the potential clinical impact of EFX.

Phase 3 SYNCHRONY Outcomes Trial: A New Hope for Patients with Compensated Cirrhosis

Akero Therapeutics has recently commenced the SYNCHRONY Outcomes study, a Phase 3 trial aimed at assessing the efficacy and safety of EFX in patients with compensated cirrhosis (F4) due to MASH. As these patients face a significant risk of developing liver-related complications and mortality, the need for an effective treatment option is paramount. The initiation of this trial represents a major stride forward in addressing the unmet medical need in this patient population.

Phase 2b HARMONY Study: Promising Histological Improvements

In the Phase 2b HARMONY study, Akero Therapeutics reported compelling week 96 results, demonstrating the potential of EFX in improving fibrosis stages without exacerbating MASH. The study showed that patients receiving EFX at 50mg and 28mg doses achieved a one-stage improvement in fibrosis, exceeding the placebo response rate by three- and two-fold, respectively. These remarkable findings are highly indicative of EFX's potential to halt or even reverse the progression of liver fibrosis in patients with MASH.

Implications for Patient Care

The results from both the Phase 2b HARMONY study and the initiation of the Phase 3 SYNCHRONY Outcomes trial hold significant implications for patient care. A treatment that can effectively address the underlying causes of MASH and halt disease progression could potentially reduce the risk of complications and improve patient outcomes in those with compensated cirrhosis. EFX has the potential to be a transformative therapeutic option that may change the landscape of treatment for this patient population.


The initiation of the Phase 3 SYNCHRONY Outcomes trial by Akero Therapeutics and the encouraging results from the Phase 2b HARMONY study provide new hope in the treatment of patients with compensated cirrhosis due to MASH. Efruxifermin (EFX) has shown impressive potential in improving fibrosis stages without worsening MASH, ushering in a new era in the management of this challenging condition. As ongoing research continues to elucidate the full therapeutic capabilities of EFX, patients and healthcare providers eagerly anticipate the possibility of a much-needed breakthrough in the treatment of compensated cirrhosis due to MASH.

Sources for this article: Akero Therapeutics Inc Press release, News Wire, Globe Newswire, Business wire, Pr newswire.... and Supply Chain Analysis by CSIMarket.com


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com